ARCALYST (rilonacept)

Self-Administration – subcutaneous injection

 

Diagnosis considered for coverage:

 

  • Cryopyrin-Associated Periodic Syndromes (CAPS): Indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and pediatric patients 12 years and older.
  • Deficiency of Interleukin-1 Receptor Antagonist (DIRA): Indicated for the maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing at least 10 kg.
  • Recurrent Pericarditis: Indicated for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and pediatric patients 12 years and older.

 

Coverage Criteria:

 

For diagnosis of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and/or Muckle-Wells Syndrome (MWS):

 

  • Documented diagnosis of CAPS including FCAS or MWS; AND
  • Prescribed by or in consultation with one of the following:
    • Immunologist
    • Allergist
    • Dermatologist
    • Rheumatologist
    • Neurologist
    • Specialist with expertise in the management of CAPS; AND
  • The medication will not be used in combination with another biologic agent.

 

For diagnosis of Deficiency of Interleukin-1 Receptor Antagonist (DIRA):

 

  • Documented diagnosis of DIRA; AND
  • Patient weighs at least 10 kg; AND
  • Patient is currently in remission (e.g., no fever, skin rash, and bone pain; no radiological evidence of active bone lesions; C-reactive protein [CRP] less than 5 mg/L).

 

For diagnosis of Recurrent Pericarditis:

 

  • Diagnosis of recurrent pericarditis as evidenced by at least 2 episodes that occur a minimum of 4 to 6 weeks apart; AND
  • Prescribed by or in consultation with a cardiologist; AND
  • Trial and failure, contraindication, or intolerance to at least one of the following:
    • nonsteroidal anti-inflammatory drugs (e.g., ibuprofen, naproxen)
    • colchicine
    • corticosteroids (e.g., prednisone).

 

Reauthorization Criteria:

 

For diagnosis of CAPS including FCAS or MWS:

 

  • Patient has experienced disease stability or improvement in clinical symptoms while on therapy as evidenced by one of the following:
    • Improvement in rash, fever, joint pain, headache, or conjunctivitis
    • Decreased number of disease flare days
    • Normalization of inflammatory markers (C-reactive protein [CRP], erythrocyte sedimentation rate [ESR], serum amyloid A [SAA])
    • Corticosteroid dose reduction
    • Improvement in MD global score or active joint count

 

For diagnosis of Recurrent Pericarditis:

 

  • Documentation of positive clinical response to therapy

 

Dosing:
 

CAPS/FCAS/MWS; Recurrent Pericarditis:

  • Adults: Initiate treatment with a loading dose of 320 mg delivered as two, 2-mL subcutaneous injections of 160 mg each, administered on the same day at two different injection sites. Continue dosing with a once-weekly injection of 160 mg administered as a single, 2-mL subcutaneous injection.
  • Pediatrics (12-17yr old): Initiate treatment with a loading dose of 4.4 mg/kg, up to a maximum dose of 320 mg, administered as one or two subcutaneous injections, not to exceed single-injection volume of 2 mL per injection site. If the initial dose is given as two injections, administer on the same day at two different sites. Continue dosing with a once-weekly injection of 2.2 mg/kg, up to a maximum of 160 mg, administered as a single subcutaneous injection, up to 2 mL.
  • If a once-weekly dose is missed, instruct the patient to administer the injection within 7 days from the missed dose and then resume the patient’s original schedule. If the missed dose is not administered within 7 days, instruct the patient to administer the dose, starting a new schedule based on this date.

 

DIRA:

  • Adults: The recommended dose of ARCALYST is 320 mg, once weekly, administered as two subcutaneous injections on the same day at two different sites with a maximum single-injection volume of 2 mL. ARCALYST should not be given more often than once weekly.
  • Pediatrics (weighing 10kg or more): The recommended dose of ARCALYST is 4.4 mg/kg (up to a maximum of 320 mg), once weekly, administered as one or two subcutaneous injections with a maximum single-injection volume of 2 mL. If the dose is given as two injections, administer both on the same day, each one at a different site.
  • When switching from another IL-1 blocker (e.g., Kineret, Ilaris), discontinue the IL-1 blocker and begin ARCALYST treatment at the time of the next dose.

 

Coverage Duration:

 

  • 1 year

 

Authorization is not covered for the following:
  • The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.

 

Additional Information:
  • CAPS refer to rare genetic syndromes generally caused by mutations in the NLRP-3 [Nucleotide-binding domain, leucine rich family (NLR), pyrin domain containing 3] gene (also known as Cold-Induced Auto-inflammatory Syndrome-1 [CIAS1]). CAPS disorders are inherited in an autosomal dominant pattern with male and female offspring equally affected. Features common to all disorders include fever, urticaria-like rash, arthralgia, myalgia, fatigue, and conjunctivitis. In most cases, inflammation in CAPS is associated with mutations in the NLRP-3 gene which encodes the protein cryopyrin, an important component of the inflammasome. Mutations in NLRP-3 result in an overactive inflammasome resulting in excessive release of activated IL-1β that drives inflammation.

 

Policy Review History:
  • 06/01/2023 – New utilization management program for established drug approved by P&T (05/16/2023).

 

References:
  1. Arcalyst Prescribing Information. Regeneron Pharmaceuticals. Zug, Switzerland. May 2021.
  2. Aksentijevich I, Putnam CD, Remmers EF, et al. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American Patients and a new cryopyrin model. Arthritis Rheum. 2007; 56(4):1273-1285.
  3. McDermott M, Aksentijevich I. The auto-inflammatory syndromes. Curr Opin Allergy Clin Immunol. 2002; 2:511-516.
  4. Chiabrando JG, Bonaventura A, Vecchie A, et al. Management of acute and recurrent pericarditis. J Am Coll Cardiol. 2020;75(1):76–92.
  5. Klein AL, Imazio M, Cremer P, et al. Phase 3 trial of interleukin-1 trap rilonacept in recurrent pericarditis. N Engl J Med 2021;384:31-41.

    Last review date: June 1, 2023

    Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone